BeOne Medicines Ltd.·4

Feb 6, 4:57 PM ET

Lee Chan Henry 4

Research Summary

AI-generated summary

Updated

BeOne Medicines (ONC) SVP Lee Chan Henry Exercises Options, Sells Shares

What Happened

  • Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), executed a set of option/derivative transactions and completed open-market sales on Feb 4, 2026. He exercised 1,660 shares via option/derivative exercises (three exercises) by paying roughly $317,721 in aggregate exercise cost, and sold the same number of shares (1,660) in two open-market transactions for total cash proceeds of about $580,197.
  • The Form 4 also reports conversion/disposition of additional derivative securities (three entries) totaling 21,580 shares shown with $0 proceeds (these entries reflect conversions/exercises of derivative securities, per the filing). The sale transactions were effected pursuant to a Rule 10b5-1 trading plan.

Key Details

  • Transaction date: February 4, 2026; Form 4 filed Feb 6, 2026 (timely filing).
  • Option exercises (acquired): 502 shares @ $194.47 = $97,624; 662 shares @ $213.32 = $141,218; 496 shares @ $159.03 = $78,879. Total exercise cost ≈ $317,721.
  • Open-market sales (disposed): 664 shares @ $348.79 = $231,597; 996 shares @ $350.00 = $348,600. Total proceeds ≈ $580,197.
  • Derivative conversions/dispositions (reported as $0 proceeds): 6,526; 8,606; and 6,448 shares (total 21,580) — listed as exercise/conversion of derivative securities.
  • Notable footnotes: F2 — sales were made under a Rule 10b5-1 trading plan adopted May 14, 2025. F1 — each American Depositary Share (if applicable) represents 13 ordinary shares. F3–F6 — vesting schedules and that option/exercise figures are represented in ordinary shares.
  • Shares owned after the transactions: not specified in the excerpt of the filing.

Context

  • The filing shows option/derivative exercises (Form 4 code M) and contemporaneous open-market sales (Form 4 code S). Exercising options and then selling shares the same day is common (e.g., to cover exercise costs or taxes), but the filing does not state the insider’s motive.
  • The sales were performed under a pre-arranged 10b5-1 plan, which indicates the trades were executed according to a previously adopted plan rather than ad hoc decisions.
  • Derivative entries at $0 are conversions/exercises of derivative securities (e.g., option/RSU settlements); these are procedural steps and do not necessarily imply additional cash proceeds.